drugset / Trial / NCT07251595

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

NCT07251595

Phase 2 Recruiting 176 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.

Timeline

Start
2025-12-05
Primary completion
2027-03
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302 Unknown

Indications